Last updated: June 13, 2026
MEPHYTON (Phytomenadione/Vitamin K1) clinical trials update, market analysis, and exclusivity-driven launch projection
MEPHYTON is a brand of phytomenadione (vitamin K1) used for vitamin K deficiency and reversal of anticoagulation. A market and clinical-trial update requires a drug-specific evidence base (FDA labeling, NDC/labeler, Orange Book listings, and a trials registry record tied to the exact brand/strength). No drug-specific patent, exclusivity, or clinical-trials dataset tied to “MEPHYTON” can be validated from the information provided, so a complete, accurate clinical-trials update and projection cannot be produced under the operating constraints.
Clinical trials update for Mephyton: what studies are active and what results changed recently?
No validated, brand-specific clinical-trials record for MEPHYTON is available in the prompt context. A trials update cannot be stated without a record keyed to the brand, active moiety, dose form, route (oral vs IV), and sponsor identifiers.
Which indications do Mephyton trials target (vitamin K deficiency, warfarin reversal, pediatrics)?
No validated trials dataset for MEPHYTON can be produced from the provided inputs.
What endpoints are measured (INR correction, bleeding outcomes, time-to-coagulation normalization)?
No validated endpoint reporting for MEPHYTON can be provided.
MEPHYTON market analysis: who sells it, what are the pricing and volume drivers, and where is demand growing?
No validated market sizing, channel data, or brand-specific pricing history for MEPHYTON is present in the prompt context. A market analysis cannot be produced accurately without at least one of: confirmed NDC/labeler, geographies, formulation (oral vs injectable), strength, or payer/wholesale benchmarks tied to the brand.
What segments matter most (hospital IV use vs outpatient oral prophylaxis)?
No segment-level demand data tied to MEPHYTON can be stated.
How do shortages, supply chain constraints, or generic substitution affect Mephyton availability?
No MEPHYTON-specific supply constraints or substitution patterns can be validated from the prompt context.
When does Mephyton lose exclusivity or face generic entry risk?
A loss-of-exclusivity and generic entry risk analysis requires Orange Book and patent estate data for the specific product (NDA/BLA, strength, dosage form, route). The prompt provides none of those identifiers. A legally and commercially actionable exclusivity projection cannot be produced.
What patents protect Mephyton (active ingredient, formulation, method-of-use), and which are likely to expire first?
No patent numbers, assignees, or expiration dates for MEPHYTON are available in the prompt context.
What Paragraph IV challenges or biosimilar-like pathways apply to vitamin K1 products?
No validated FDA legal-status record is available.
What is the Orange Book status of MEPHYTON (listed patents, expiration dates, and exclusivity blocks)?
Orange Book status cannot be stated without the product’s NDA holder, application number, and dosage-form mapping.
How strong is the patent estate for vitamin K1 products like MEPHYTON, and what does that mean for R&D and licensing?
Patent strength requires a mapped claim set, jurisdictional coverage, remaining term, and litigation history. No such estate can be validated for “MEPHYTON” from the provided inputs.
What generic launch scenarios exist for Mephyton, and how soon could competitors enter?
Competitor entry timing depends on product-specific exclusivities, listed patents, and regulatory pathways. No product identifiers or FDA status are available, so launch timing cannot be projected.
How does MEPHYTON compare with alternative vitamin K1 products (vitamin K1 injectable and oral brands)?
A competitive comparison requires confirmed formulation equivalence, product strengths, route-of-administration differences, and verified FDA labeling. The prompt context does not provide the necessary brand and formulation mapping.
What patent litigation affects MEPHYTON or vitamin K1 brands, and what settlements changed the launch timetable?
No litigation docket identifiers or patent case records tied to MEPHYTON are provided, so no litigation impact can be reported.
FDA regulatory status for MEPHYTON: approvals, labeling scope, and pathway implications
Regulatory status cannot be validated without FDA application number, label updates, and product composition mapping.
Key Takeaways
- A complete clinical-trials update for MEPHYTON cannot be produced without a brand-specific trials record tied to the exact dosage form and route.
- A market analysis and projection cannot be produced without verified brand-specific supply, pricing, geography, and sales benchmarks.
- An exclusivity and generic-entry projection cannot be produced without Orange Book mapping to the exact MEPHYTON product (NDA, strength, dosage form, route) and its listed patents.
FAQs
- Which FDA application (NDA number) corresponds to MEPHYTON, and what dosage forms are included?
- Is MEPHYTON supplied as oral vs injectable vitamin K1, and how do route differences affect hospital demand?
- What vitamin K1 strengths are used for warfarin reversal, and what label language drives utilization?
- Are there any listed Orange Book patents for MEPHYTON, and what are their expiration dates by strength?
- Have any MAAs or NDAs used a Para-IV strategy against vitamin K1 brand products in the last 5 years?
References (APA)
- Not available from the provided prompt context.
